<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2270640607-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2270640607-430x241.jpg"/></p>
<p>Genmab 的首席执行官 Jan van de Winkel 表示，投资将集中在公司晚期管线的其他领域。图片来源：claudenakagawa via Shutterstock.com。</p>
<p>Genmab 已停止开发 acasunlimab，这是一种在针对固体肿瘤（包括非小细胞肺癌（NSCLC））的中晚期试验中的双特异性抗体。</p>
<p>Genmab 对细节保持简短，表示这一决定是作为 “战略聚焦于其管线中最具价值创造机会” 的一部分做出的。该制药公司还进行了 “对不断变化的竞争格局的全面评估”，这导致了 acasunlimab 项目的取消。管线优先级调整预计不会影响公司 2025 年的全年财务指引。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Ascrinvacumab 在肝癌中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Pacmilimab 在非小细胞肺癌中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现有效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>虽然 Genmab 表示该癌症候选药物的临床特征令人鼓舞，但公司将把重点转向其他肿瘤抗体。这包括 Epkinly（epcoritamab）、petosemtamab 和 rinatabart sesutecan（Rina-S），这些药物正在进行晚期试验。公司最近通过其 $80 亿收购 Merus 获得了 petosemtamab 的使用权。</p>
<p>Genmab 的首席执行官 Jan van de Winkel 表示：“尽管数据令人鼓舞，但我们在晚期管线中看到的有吸引力的机会促使我们将投资集中在我们认为能够为患者和股东带来最大利益的地方。”</p>
<p>在 2024 年，Genmab 在其合作伙伴 BioNTech 决定不推进该资产后，获得了 acasunlimab 的全部开发和商业化权利。Acasunlimab 是一种双特异性抗体，旨在通过同时靶向 PD-L1 和 4-1BB 来产生抗肿瘤反应。</p>
<p>到目前为止，acasunlimab 正在与 MSD 的 Keytruda（pembrolizumab）联合评估，用于 NSCLC 治疗的 III 期试验（NCT06635824）。2024 年 6 月在该患者群体中报告的 II 期试验数据显示，12 个月的中位总生存期（OS）为 17.5 个月。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>Acasunlimab 还在进行黑色素瘤的 II 期开发和固体肿瘤的 I 期开发。</p>
<p>William Blair 分析师 Matt Phipps 表示：“我们认为这是正确的决定，考虑到 II 期试验中整体生存曲线的近期恶化，且这并未影响我们认为在 2026 年大型生物技术领域的最佳机会之一，Epkinly、Rina-S 和 petosemtamab 的关键关键读数即将发布。我们看到公司三项主要资产的潜在峰值销售额可达 80 亿美元，因此对 Genmab 有显著的上行空间。”</p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p>制药技术卓越奖 的提名现已关闭。感谢所有参与的组织，你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>行动中的卓越</strong></p>
<p>Upperton Pharma Solutions 因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖。Upperton Pharma Solutions 正在迅速扩展其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发转向临床和小众商业供应，减少交接和加快时间。</p>
<p>发现影响</p>

GMAB

<p>Genmab 已停止开发用于肺癌的双特异性抗体 acasunlimab，此举是在对其产品线进行战略审查后做出的。该公司将专注于其他肿瘤学候选药物，包括正在进行后期试验的 Epkinly 和 petosemtamab。首席执行官 Jan van de Winkel 强调了优先投资高价值机会的必要性。尽管做出了这一决定，Genmab 对 2025 年的财务指引保持不变。分析师 Matt Phipps 支持这一举措，指出对 acasunlimab 试验的生存数据的担忧，同时强调了 Genmab 其他资产的潜力</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2270640607-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2270640607-430x241.jpg"/></p>
<p>Genmab’s CEO Jan van de Winkel said investments will be focused in other areas of the company’s late-stage pipeline. Image credit: claudenakagawa via Shutterstock.com.</p>
<div class="lb-trans"><p>Genmab 的首席执行官 Jan van de Winkel 表示，投资将集中在公司晚期管线的其他领域。图片来源：claudenakagawa via Shutterstock.com。</p>
</div><p>Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including non-small cell lung cancer (NSCLC).</p>
<div class="lb-trans"><p>Genmab 已停止开发 acasunlimab，这是一种在针对固体肿瘤（包括非小细胞肺癌（NSCLC））的中晚期试验中的双特异性抗体。</p>
</div><p>Genmab remained brief on details, saying the decision was made as part of a “strategic focus on the most value‑creating opportunities” in its pipeline. The pharma company also conducted a “thorough assessment of the evolving competitive landscape”, which resulted in the acasunlimab programme being axed. The pipeline prioritisation move is not expected to impact the company’s full‑year 2025 financial guidance.</p>
<div class="lb-trans"><p>Genmab 对细节保持简短，表示这一决定是作为 “战略聚焦于其管线中最具价值创造机会” 的一部分做出的。该制药公司还进行了 “对不断变化的竞争格局的全面评估”，这导致了 acasunlimab 项目的取消。管线优先级调整预计不会影响公司 2025 年的全年财务指引。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Ascrinvacumab in Liver Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Ascrinvacumab 在肝癌中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Pacmilimab in Non-Small Cell Lung Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Pacmilimab 在非小细胞肺癌中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现有效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>While Genmab stated that the cancer candidate’s clinical profile has been encouraging, the company will instead pivot its focus to other oncology antibodies. This includes Epkinly (epcoritamab), petosemtamab and rinatabart sesutecan (Rina‑S), which are in late-stage trials. The company only gained access to petosemtamab recently via its $8bn acquisition of Merus in September.</p>
<div class="lb-trans"><p>虽然 Genmab 表示该癌症候选药物的临床特征令人鼓舞，但公司将把重点转向其他肿瘤抗体。这包括 Epkinly（epcoritamab）、petosemtamab 和 rinatabart sesutecan（Rina-S），这些药物正在进行晚期试验。公司最近通过其 $80 亿收购 Merus 获得了 petosemtamab 的使用权。</p>
</div><p>Genmab’s CEO Jan van de Winkel said: “Although the data have been encouraging, the compelling opportunities we see in our late‑stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders.”</p>
<div class="lb-trans"><p>Genmab 的首席执行官 Jan van de Winkel 表示：“尽管数据令人鼓舞，但我们在晚期管线中看到的有吸引力的机会促使我们将投资集中在我们认为能够为患者和股东带来最大利益的地方。”</p>
</div><p>In 2024, Genmab assumed full development and commercialisation rights to acasunlimab after its collaboration partner BioNTech decided not to advance the asset. Acasunlimab is a bispecific antibody designed to ‌produce an anti-tumour response by targeting both PD-L1 and 4-1BB.</p>
<div class="lb-trans"><p>在 2024 年，Genmab 在其合作伙伴 BioNTech 决定不推进该资产后，获得了 acasunlimab 的全部开发和商业化权利。Acasunlimab 是一种双特异性抗体，旨在通过同时靶向 PD-L1 和 4-1BB 来产生抗肿瘤反应。</p>
</div><p>Until now, acasunlimab was being evaluated in combination with MSD’s Keytruda (pembrolizumab) for NSCLC teratment in a Phase III trial (NCT06635824). Data from a Phase II trial in this patient population reported in June 2024 demonstrated a 12-month median overall survival (OS) of 17.5 months.</p>
<div class="lb-trans"><p>到目前为止，acasunlimab 正在与 MSD 的 Keytruda（pembrolizumab）联合评估，用于 NSCLC 治疗的 III 期试验（NCT06635824）。2024 年 6 月在该患者群体中报告的 II 期试验数据显示，12 个月的中位总生存期（OS）为 17.5 个月。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>Acasunlimab was also in Phase II development for melanoma and Phase I development for solid tumours.</p>
<div class="lb-trans"><p>Acasunlimab 还在进行黑色素瘤的 II 期开发和固体肿瘤的 I 期开发。</p>
</div><p>William Blair analyst Matt Phipps said: “We believe this is the right decision, given recent deterioration of the overall survival curve from the Phase II trial with longer follow-up, and it does not detract from what we view as one of the best opportunities in large-cap biotech going into 2026, with key pivotal readouts for Epkinly, Rina-S, and petosemtamab. With potential for $8bn in combined peak sales for the company’s three lead assets, we see significant upside for Genmab.”</p>
<div class="lb-trans"><p>William Blair 分析师 Matt Phipps 表示：“我们认为这是正确的决定，考虑到 II 期试验中整体生存曲线的近期恶化，且这并未影响我们认为在 2026 年大型生物技术领域的最佳机会之一，Epkinly、Rina-S 和 petosemtamab 的关键关键读数即将发布。我们看到公司三项主要资产的潜在峰值销售额可达 80 亿美元，因此对 Genmab 有显著的上行空间。”</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>制药技术卓越奖 的提名现已关闭。感谢所有参与的组织，你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行动中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>Upperton Pharma Solutions 因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖。Upperton Pharma Solutions 正在迅速扩展其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发转向临床和小众商业供应，减少交接和加快时间。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>发现影响</p>
</div>

Genmab 搁置了其 III 期肺癌候选药物的开发